About
Technology
Issues
FAQ
Links
Official Page
Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.